Abstract
Atypical antipsychotics present exciting opportunities to improve the quality of life for many individuals who are experiencing the debilitating impact of schizophrenia, a syndrome with complex symptom presentations and unclear cause. In the past the antipsychotic efficacy was thought to correlate with the degree of dopamine blockade; this hypothesis has several limitations. Atypical antipsychotics hold promise for reduced side effects and improved efficacy in treating negative symptoms, possibly through the interactions of neurotransmitters such as serotonin and dopamine. Similar to clozapine, olanzapine (Zyprexa) has a bigh affinityfor a number of subtypes of dopamine receptors and other neurotransmitters. The interrelationship of its actions at multiple receptor sites may account for its improved efficacy in treating negative symptoms and its unique side effect profile.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the American Psychiatric Nurses Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
